Commercial Development. During the term of this Agreement, Company agrees to use commercially reasonable efforts to effectively manufacture and market Licensed Products. Such efforts will include sublicensing, development of promotional literature, mailings, and journal advertisements.
Commercial Development. The European Commercial Development team is responsible for commercial strategy formulation across the European area, including both product and sales force strategy. The HQ marketing team will work closely with the Clinton, NJ-based marketing team to develop a cohesive global strategy suitable for implementation in European markets. The European team will have responsibility to ensure that brand strategies are implemented consistently across the area, and will perform market research to monitor performance and adjust strategy as appropriate. The team will also work in concert with country GMs and local marketing management to implement large-scale promotional and educations programs. The European HQ team will also develop and implement European sales force strategies including development and maintenance of a customer relationship management system, sales skills training programs, and sales leadership development. The HQ team will work closely with LOC commercial management to ensure a top-class sales effort in each country. Anticipated headcount: 5
Commercial Development. (1) Preference should be given first to water-dependent commercial uses over nonwater- dependent commercial uses; and second, to water-related and water-enjoyment commercial uses over nonwater-oriented commercial uses.
(2) Public access and ecological restoration should be considered as potential mitigation of impacts to shoreline resources and values for all water-related or water-dependent commercial development unless such improvements are demonstrated to be infeasible or inappropriate.
Commercial Development. The Project, as contemplated by this Agreement and as depicted in the Conceptual Site Plan, will consist of approximately two hundred fifty thousand (250,000) square feet of building space. The site layout of the commercial portion of the Project must conform generally to the arrangement of buildings as depicted in the Conceptual Site Plan. Developer may submit commercial buildings individually or in groups of buildings to the City for development review approval, and the approval process for such submissions will proceed for the building or buildings submitted without the requirement that other buildings proceed through the development review process simultaneously.
Commercial Development. 5.1 SGI shall, upon MAB's request, keep MAB generally informed of SGI's and its Affiliates' updated development plans for Licensed Products, including SGI's and its Affiliates' and sublicensees' planned timing for Licensed Product launch dates. All dates and other information provided by SGI to MAB shall be Confidential Information (as defined below), shall used by MAB for planning purposes only and shall be subject to modification by SGI, at any time, based on its or its Affiliates' and sublicensees' actual progress in the development process.
5.2 SGI shall provide MAB with notice of regulatory approvals received by SGI or its Affiliates or sublicensees' regarding Licensed Products.
Commercial Development. The commercial development will be located principally on the mound portion of the refuse fill area. The project design has been developed specifically to avoid or minimize activities that would require the removal or penetration of the soil cap. However, this section identifies a number of potential construction activities that could impact the integrity and quality of the existing cap. Commercial development activities will begin with the surcharging of the mound area. Surcharging involves the placement of eight feet or more of soil on the ground surface to promote settling of refuse and bay mud to reduce the settlement potential after site development. The soil is left in place for three months, and then is moved to another area of the site. A minimum of four feet of soil will be left over the refuse upon completion of surcharging. This remaining cap will likely be more dense as a result of the surcharging and grading process. The developer plans to perform surcharging tests to select the optimum soil surcharge depth. Such testing is intended to prevent the use of excessive soil loadings that could lead to a differential settlement of the mound area and the creation of cracks or fissures in the existing cap. 192 A few of the buildings and parking lots may require the excavation of refuse and re-establishment of the cap at a lower grade. only preliminary site elevations have been established at this time, therefore the extent of such excavations, if any, has not been determined. Plans call for avoiding excavation whenever possible. If cap removal were necessary, preliminary estimates are that it is unlikely to occur over more than 8,000 square feet of the site at any one time. Excavations for utilities are not expected to exceed the cap depth in most cases. Current plans call for utility lines to be located in common trenches wherever possible to reduce the amount of excavation. Where it is necessary to penetrate the cap, the developers have indicated that the extent of open trench at any one time can be limited, and trenches can be backfilled daily. The developers have indicated that open trenches are unlikely to exceed the dimensions of 3 by 200 feet (600 square feet) at any one time. Foundation excavations will be made within the cap soils. The commercial buildings will not require pilings or footings that will penetrate the refuse fill cap. No other significant cap disturbing activities have been identified that will be associated with the commercial...
Commercial Development. 7.01 CENTOCOR shall use its best efforts, including such efforts of any or all of its affiliates and licensees, commercially to develop, manufacture and distribute products throughout the world.
7.02 At intervals no longer than every twelve (12) months, CENTOCOR shall report in writing to XXXX-XXXXXX on progress made toward commercialization, manufacturing and distribution of the products and royalties earned thereon, and if at any time progress is not considered reasonable, XXXX-XXXXXX may terminate this agreement upon notice to CENTOCOR and according to provisions of section 10.02.
7.03 CENTOCOR agrees to use nomenclature specified by Xx. Xxxxxx Xxxx, Jr. and Xx. Xxxxxx X. Knapp, unless otherwise authorized in writing by XXXX-XXXXXX, to identify the hybridomas for the purposes of publication, promotion and commercial development of the hybridomas, but shall not identify either XXXX- XXXXXX, nor Xx. Xxxxxx Xxxx, Jr., nor Xx. Xxxxxx X. Knapp, nor their XXXX-XXXXXX collaborators as being the source of the antibodies and/or hybridomas; except that any publication may refer to the published record. CENTOCOR will allow Drs. Xxxx and Xxxxx to comment on any advertising as it relates to the XXXX-XXXXXX prior to publication by CENTOCOR.
Commercial Development. A. HEMISPHERX has or will provide SCIEN:
1. As an Integral Part of this Agreement and in order for HEMISPHERX to ship Product to SCIEN, the letter with attachments (Exhibit 1) must be signed by an officer of SCIEN. A protocol is also provided (Exhibit 2).
2. All the appropriate information about Products that will assist with the education of physicians about the Product in the Territory.
3. Ongoing scientific and medical support.
4. Product Units in quantities sufficient for SCIEN's Direct Access/EAP and RAA commercial needs in the Territory, subject to availability from HEMISPHERX.
B. SCIEN will:
1. Within 60 days after this Agreement becomes effective, prepare and provide a Business Plan, to be attached to this Agreement as Exhibit 3, to make aware and educate physicians and patients about Product both prior to and following approval of Product.
2. Assist in determining reimbursable End User pricing of Product and gain reimbursement for Product under Direct Access/EAP program and RAA sales of the Product in the Territory.
3. Assist physicians who desire to administer Product with the required paperwork under any Direct Access/EAP program.
4. Manage the logistics within the Territory from arrival to End User supply.
6. Assist HEMISPHERX to gain regulatory approval of Product in the Field in the Territory
7. Prepare and provide a 3-year post regulatory approval Sales, Marketing, and Distribution Plan including a 3-year minimum sale forecast and a committed-dollar field sales force, product manager and marketing budget to be agreed by both Parties and a non-binding 12 month Product forecast no later than six (6) months prior to the anticipated registration and subsequent launch date for each Product, also to be agreed by both parties,
8. Pay for all the above Sales Marketing and Distribution activities and related expenses.
9. Hold 3 months inventory of the forecasted sales once the product is registered.
10. If needed, assist in recruiting clinical trial sites and principal investigators in the Field in the Territory.
11. Provide HEMISPHERX a monthly written report of SCIEN's efforts and status thereof under this Agreement.
Commercial Development. During the term of this Agreement, PhytoMedical agrees to use commercially reasonable efforts to effectively manufacture and market Licensed Products. Such efforts will include sublicensing, development of promotional literature, mailings, and journal advertisements.
Commercial Development.
(1) Commercial development should be prohibited in shoreline jurisdiction, consistent with City zoning.
